The aim of this study was to investigate the effect of charge carrier lipid on the skin penetration, retention, and hair growth of topically applied fi nasteride-containing liposomes. Finasteride-containing liposomes were prepared by traditional thin fi lm hydration method using Phospholipon ® 85 G and cholesterol with or without charge carrier lipid (1,2 dimyristoyl-sn-glycero-3-phosphate or 1,2-dioleoyl-trimethylammonium-propane for anionic and cationic charge, respectively). Freshly prepared fi nasteride-containing liposome suspension was applied on the hairless mouse skin, and skin penetration and retention were measured using KesharyChien diffusion cell. Non-liposomal formulation (ethanol 10% solution containing 0.5 mg/ml of FNS) was also used as a control. The amount of fi nasteride in the diffusion cell and mouse skin was measured by HPLC. The hair growth was evaluated using depilated male C57BL/6N mice. Mean particle size of all fi nasteride-containing liposomes was less than a micron, and polydispersity index revealed size homogeneity. Skin penetration and retention studies showed that signifi cantly less amount of fi nasteride was penetrated when applied as anionic liposome while more amount of the drug was retained. Specifi cally, in liposome prepared with 10% anionic charge carrier lipid, penetration was 12.99 μg/cm 2 while retention was 79.23 μg/cm 2 after 24 h of application. In hair growth study, fi nasteride-containing anionic liposomes showed moderate effi cacy, but the effi cacy was not found when applied as cationic liposomes. In conclusion, topical application of fi nasteride using anionic liposome formulation appears to be useful option for the treatment of androgenetic alopecia to avoid systemic side effects of the drug.
INTRODUCTION
Androgenetic alopecia, also referred to as male-pattern hair loss or common baldness in men, affects at least 50% of men by the age of 50 and up to 70% of all men in later life (Norwood, 1975) . Although there is no treatment to completely reverse androgenetic alopecia in advanced stage, treatment with minoxidil or fi nasteride (or combination of both) can slow down and partly reverse the progression in the majority of patients who have mild to moderate stage (Otberg et al., 2007) . The US Food and Drug Administration approved topical solution of minoxidil and low-dose fi nasteride (FNS) for the treatments of the hair loss and androgenetic alopecia. FNS ( Fig. 1) There have been several studies which showed that topical application of the drug might be better option to avoid the unwanted side effects encountered when orally administered (Tabbakhian et al., 2006; Kumar et al., 2007) . Specifi cally, since the target tissue of FNS for the treatment of androgenetic alopecia is hair follicles in the scalp, various topical formulation of the drug was pursued using liposomes, ethosomes, niosomes, solid lipid nanoparticles, and nanostructured lipid carriers (Biruss and Valenta, 2006; Biruss et al., 2007; Rao et al., 2008; Balakrishnan et al., 2010) .
In present study, we prepared charged liposome formulations of FNS in an attempt to enhance delivery of the drug to the target tissue (hair follicle) using phosphatidylcholine, cholesterol, and charge carrier lipids. 1,2-Dimyristoyl-sn-glycero-3-phosphate monosodium salt (DMPA, negative charge) or 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP, positive charge) was used as negative or positive charge carrier lipid, respectively. Liposome without charge carrier lipid was also prepared for comparison by the same procedure. We performed hair growth study of FNS-containing liposomes using C57BL/6N mice. We also performed evaluation of physical properties, skin penetration and retention studies for FNS-containing liposomes.
MATERIALS AND METHODS

Materials
Phospholipon ® 85G (PL) was generously provided by the Phospholipid GmbH (Nattermannallee, Germany). Cholesterol (CH) was obtained from Wako Pure Chemical Industries (Osaka, Japan). FNS was kindly gifted from Dong-A Pharmaceutical Co., Ltd. South Korea, and ibuprofen was obtained from Sigma Chemical Co., (St. Louis, USA). Dialysis bag (Spectra/Por no. 2, MWCO: 12,000-14,000 g/mole) was purchased from Spectrum Laboratories Inc. (Rancho Dominguez, USA). 1,2-Dimyristoyl-sn-glycero-3-phosphate monosodium salt (DMPA) and 1, 2-dioleoyl-trimethylammonium-propane chloride salt (DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL). All other chemicals were of analytical grade and used without further purifi cation.
Preparation of FNS-containing liposomes
FNS-containing liposomes were prepared by traditional thin fi lm hydration method. Composition of FNS-containing liposomes is listed in Table 1 . Accurately weighed amount of each constituent was transferred to a 100-ml round bottom fl ask and dissolved in a mixture of chloroform and methanol (2:1, v/v). The organic solvent was removed under vacuum by rotary evaporator at 35 o C for 15 min to form a thin fi lm on the wall of the fl ask. Subsequently, the residual organic solvent was suctioned for 2 h to ensure complete removal. The dried lipid fi lm was hydrated with 20 ml of distilled water for 2 h at 60 o C with gentle agitation. The liposome thus obtained was allowed to anneal overnight at 4 o C and sonicated for 10 min in bath sonicator (42 KHz) for size reduction. The resultant dispersion was transferred to nitrogen purged vials and stored at 4 o C until further studies.
Physical properties of liposomes
Particle size and zeta potential of FNS-containing liposomes were measured by electrophoretic light scattering spectrometer (ELS-8000, OTSUKA Electronics Co. Ltd., Japan) at room temperature. FNS-containing liposome suspension was diluted with distilled water before the measurement to adjust the intensity. The system was used in the auto-measuring mode at 80 mV. Polydispersity index was also determined as a measurement of particle size homogeneity of the prepared liposomes. A small value of polydispersity index (<0.3) indicates homogeneous liposome population.
HPLC assay
FNS was determined using HPLC system (Shimadzu, Japan) equipped with Class VP computer software, LC 10 AD VP pump, and SPD 10A UV-VIS detector at 210 nm. Column used was Inertsil ODS-3 (4.6×150 mm, GL Science Inc, Japan) and the mobile phase consisted of acetonitrile and distilled water (60:40) adjusted to pH 2.8 with phosphoric acid. Ibuprofen was used as internal standard for the assay. Flow 
